NASDAQ:EDIT - Nasdaq - US28106W1036 - Common Stock - Currency: USD
NASDAQ:EDIT (5/2/2025, 10:02:16 AM)
1.665
+0.04 (+2.78%)
The current stock price of EDIT is 1.665 USD. In the past month the price increased by 37.29%. In the past year, price decreased by -71.43%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.05 | 346.01B | ||
AMGN | AMGEN INC | 13.4 | 149.58B | ||
GILD | GILEAD SCIENCES INC | 13.43 | 129.37B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1733.55 | 129.24B | ||
REGN | REGENERON PHARMACEUTICALS | 13.64 | 65.27B | ||
ARGX | ARGENX SE - ADR | 343.26 | 39.82B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.64B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.83B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.13B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 21.25B | ||
NTRA | NATERA INC | N/A | 21.08B | ||
BIIB | BIOGEN INC | 7.67 | 17.77B |
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 246 full-time employees. The company went IPO on 2016-02-03. The company has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. The company is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.
EDITAS MEDICINE INC
11 Hurley St
Cambridge MASSACHUSETTS 02141 US
CEO: James C. Mullen
Employees: 265
Company Website: https://www.editasmedicine.com/
Investor Relations: https://ir.editasmedicine.com
Phone: 16174019000
The current stock price of EDIT is 1.665 USD. The price increased by 2.78% in the last trading session.
The exchange symbol of EDITAS MEDICINE INC is EDIT and it is listed on the Nasdaq exchange.
EDIT stock is listed on the Nasdaq exchange.
22 analysts have analysed EDIT and the average price target is 3.83 USD. This implies a price increase of 129.73% is expected in the next year compared to the current price of 1.665. Check the EDITAS MEDICINE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
EDITAS MEDICINE INC (EDIT) has a market capitalization of 139.38M USD. This makes EDIT a Micro Cap stock.
EDITAS MEDICINE INC (EDIT) currently has 265 employees.
EDITAS MEDICINE INC (EDIT) has a support level at 1.53 and a resistance level at 1.63. Check the full technical report for a detailed analysis of EDIT support and resistance levels.
The Revenue of EDITAS MEDICINE INC (EDIT) is expected to decline by -75.47% in the next year. Check the estimates tab for more information on the EDIT EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
EDIT does not pay a dividend.
EDITAS MEDICINE INC (EDIT) will report earnings on 2025-05-06, before the market open.
EDITAS MEDICINE INC (EDIT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.88).
The outstanding short interest for EDITAS MEDICINE INC (EDIT) is 15.19% of its float. Check the ownership tab for more information on the EDIT short interest.
ChartMill assigns a technical rating of 3 / 10 to EDIT. When comparing the yearly performance of all stocks, EDIT is a bad performer in the overall market: 80.18% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to EDIT. EDIT has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months EDIT reported a non-GAAP Earnings per Share(EPS) of -2.88. The EPS decreased by -40.49% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -69.41% | ||
ROE | -176.57% | ||
Debt/Equity | 0.39 |
ChartMill assigns a Buy % Consensus number of 71% to EDIT. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of 46.08% and a revenue growth -75.47% for EDIT